Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study August 12, 2026
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures May 20, 2026
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases March 11, 2026